• $3.99

Publisher Description

The founder chairman and managing director wants to make Biocon, Ltd. one of the top 10 biotech firms by 2015. The company has dealt in low-risk enzymes and generic drugs for many years. In order for the company to grow, the chairman believes that Biocon must enter the riskier business of drug discovery and development. Without making large investments into new capabilities, the company cannot become a top 10 biotech firm.

GENRE
Business & Personal Finance
RELEASED
2006
October 12
LANGUAGE
EN
English
LENGTH
15
Pages
PUBLISHER
Richard Ivey School of Business Foundation
SELLER
Ivey Business School Foundation
SIZE
2
MB

More Books by Alison Konrad